News stories about Intrexon (NYSE:XON) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intrexon earned a news impact score of 0.19 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 44.790849795532 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:
- B.C. creator of non-browning Arctic apple plans ‘aggressive expansion’ after positive U.S. test run (msn.com)
- City Council drafts letter of support for GM bug release (flkeysnews.com)
- Investor’s Watch List: Intrexon Corp (XON) – Emn News (emnnews.com)
- Intrexon Corp (XON) Receives Average Recommendation of “Hold” from Brokerages (americanbankingnews.com)
XON has been the topic of a number of analyst reports. Northland Securities reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Intrexon in a research note on Friday, November 10th. Stifel Nicolaus boosted their target price on shares of Intrexon from $39.00 to $57.00 and gave the company a “buy” rating in a research report on Friday, November 10th. Zacks Investment Research upgraded shares of Intrexon from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. Bank of America dropped their target price on shares of Intrexon from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, November 10th. Finally, ValuEngine downgraded shares of Intrexon from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $38.50.
In other Intrexon news, CEO Randal J. Kirk acquired 1,000,000 shares of the stock in a transaction on Friday, January 19th. The shares were purchased at an average price of $12.50 per share, for a total transaction of $12,500,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 55.10% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: “Intrexon (XON) Receives Media Impact Rating of 0.19” was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.com-unik.info/2018/02/19/intrexon-xon-receives-media-impact-rating-of-0-19.html.
Intrexon Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.